SCTX Scribe Therapeutics
Scribe Therapeutics earnings company data as of 4:50 AM ET 10/23
- 1 of 1 EPS beats
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 2 Dec | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 2 Sep | EPS | -3.72 | -2.62 | Beat |
| Rev | $3.1M | $1.9M | Miss -38.9% |
Insider trades
Open-market buys and sales by SCTX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $71.3M bought by 6 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
AH Bio Fund II, L.P. 10% owner, +5 joint filersBuy$5M 333,333 shares at $15.00 +16% to stakeTraded Jul 27 Filed Jul 29
-
Carl L Gordon DirectorBuy$15M 1,000,000 shares at $15.00 +287% to stakeTraded Jul 27 Filed Jul 29
-
Behzad Aghazadeh Director, +2 joint filersBuy$36.3M 2,391,238 shares at $15.16 +343% to stakeTraded Jul 24–28 Filed Jul 28
-
David Parrot CFOBuy$40K 2,666 shares at $15.00 New stakeTraded Jul 23 Filed Jul 27
-
Svetlana Lucas Chief Business OfficerBuy$45K 3,000 shares at $15.00 New stakeTraded Jul 23 Filed Jul 27
Also filed in the last 12 months, not counted as buying or selling: 5 conversions.
SEC filings
Recent issuer filings from EDGAR, 11 shown.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.